Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome

Leukemia

Volumn 23, Issue 7, 2009, Pages 1288-1296

  Zou, J X ^a   Rollison, D E ^a   Boulware, D ^a   Chen, D T ^a   Sloand, E M ^b   Pfannes, L V ^b   Goronzy, J J ^c   Bai, F ^a   Painter, J S ^a   Wei, S ^a   Cosgrove, D ^a   List, A F ^a   Epling Burnette, P K ^a,c,d  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45RA ANTIGEN; CYCLOSPORIN; L SELECTIN; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL AGING; CELL METABOLISM; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HIGH RISK PATIENT; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MEMORY T LYMPHOCYTE; MYELODYSPLASTIC SYNDROME; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; T LYMPHOCYTE SUBPOPULATION;

EID: 67650924504     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.14     Document Type: Article

References (62)

1. Lim ZY, Cook G, Johnson PR, Zuckerman M, Marks D, Wiltshire H et al Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 2007; 21: 1436-1441.
2. Sun M, Zhang J, Liu S, Liu Y, Zheng D. Sp1 is involved in 8-chloroadenosine- upregulated death receptor 5 expression in human hepatoma cells. Oncol Rep 2008; 19: 177-185.
3. Young NS. Immunosuppressive treatment of acquired aplastic anemia and immune-mediated bone marrow failure syndromes. Int J Hematol 2002; 75: 129-140.
4. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998; 102: 1314-1322.
5. Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002; 100: 3639-3645.
6. Epling-Burnette PK, Zhong B, Bai F, Jiang K, Bail RD, Garcia R et al Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001; 107: 351-362.
7. Maldonado A, Muller YM, Thomas P, Bojczuk P, O'Connors C, Katsikis PD. Decreased effector memory CD45RA+ CD62L- CD8+ T cells and increased central memory CD45RA- CD62L+ CD8+ T cells in peripheral blood of rheumatoid arthritis patients. Arthritis Res Ther 2003; 5: R91-R96.
8. Rabin RL, Roederer M, Maldonado Y, Petru A, Herzenberg LA, Herzenberg LA. Altered representation of naive and memory CD8T cell subsets in HIV-infected children. J Clin Invest 1995; 95: 2054-2060.
9. Hazenberg SA, Otto SA, Cohen Stuart JW, Verschuren MC, Borleffs JC, Boucher CA et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: A longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000; 95: 249-255.
10. Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, Wieder E et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med 1999; 5: 83-89.
11. Bennett JM, Komrokji RS. The myelodysplastic syndromes: Diagnosis, molecular biology and risk assessment. Hematology 2005; 10 (Suppl 1): 258-269.
12. Sokol RJ, Hewitt S, Booker DJ. Erythrocyte autoantibodies autoimmune haemolysis, myelodysplastic syndromes. J Clin Pathol 1989; 42 1088-1091.
13. Kook H, Zeng W, Guibin C, Kirby M, Young NS, Maciejewski JP. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol 2001; 29: 1270-1277.
14. Saunthararajah Y, Molldrem JL, Rivera M, Williams A, StetlerStevenson M, Sorbara L et al. Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: Clinical and pathophysiological features. Br J Haematol 2001; 112: 195-200.
15. Wang HQ, Shao ZH, Shi J, Cao YR, Liu H, Bai J et al. Burden of abnormal hematopoietic clone in patients with myelodysplastic syndromes. Chin Med Sci J 2006; 21: 99-103.
16. Okamoto T, Okada M, Mori A, Saheki K, Takatsuka H, Wada H et al. Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. Int J Hematol 1997; 66: 345-351.
17. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712.
18. De Rosa SC, Herzenberg LA, Herzenberg LA, Roederer M. 11color, 13-parameter flow cytometry: Identification of human naive T cells by phenotype, function, and T-cell receptor diversity. Nat Med 2001; 7: 245-248.
19. Champagne P, Ogg GS, King AS, Knabenhan C, Ellefsen K, Nobile M et al Skewed maturation of memory HIV-specific CD8T lymphocytes. Nature 2001; 410: 106-111.
20. Naylor K, Li G, Vallejo AN, Lee WW, Koetz K, Bryl E et al. The influence of age on T cell generation and TCR diversity. J Immunol 2005; 174: 7446-7452.
21. Czesnikiewicz-Guzik M, Lee WW, Cui D, Hiruma Y, Lamar DL, Yang ZZ et al. T cell subset-specific susceptibility to aging. Clin Immunol 2008; 127: 107-118.
22. Goldrath AW, Bevan MJ. Selecting and maintaining a diverse T-cell repertoire. Nature 1999; 402: 255-262.
23. Schwab R, Szabo P, Manavalan JS, Weksler ME, Posnett DN, Pannetier C et al. Expanded CD4+ and CD8+ T cell clones in elderly humans. J Immunol 1997; 158: 4493-4499.
24. Krupica Jr T, Fry TJ, Mackall CL. Autoimmunity during lymphopenia: A two-hit model. Clin Immunol 2006; 120: 121-128.
25. Marleau AM, Sarvetnick N. T cell homeostasis in tolerance and immunity. J Leukoc Biol 2005; 78: 575-584.
26. Goronzy JJ, Weyand CM. Rheumatoid arthritis. Immunol Rev 2005; 204: 55-73.
27. Fulop Jr T, Larbi A, Dupuis G, Pawelec G. Ageing, autoimmunity and arthritis: Perturbations of TCR signal transduction pathways with ageing - a biochemical paradigm for the ageing immune system. Arthritis Res Ther 2003; 5: 290-302.
28. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al. Clinical application and proposal for modification of the International Working Group (IWG response criteria in myelodysplasia. Blood 2006; 108: 419-425.
29. Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008; 26: 2505-2511.
30. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
31. Colmegna I, Diaz-Borjon A, Fujii H, Schaefer L, Goronzy JJ, Weyand CM. Defective proliferative capacity and accelerated telomeric loss of hematopoietic progenitor cells in rheumatoid arthritis. Arthritis Rheum 2008; 58: 990-1000.
32. Loughran Jr P. Anemia in lymphoproliferative disorders. Cancer Control 1998; 5: 51-53.
33. Starkebaum G, Loughran Jr TP, Gaur LK, Davis P, Nepom BS. Immunogenetic similarities between patients with Felty's syndrome and those with clonal expansions of large granular lymphocytes in rheumatoid arthritis. Arthritis Rheum 1997; 40: 624-626.
34. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997; 99: 699-705.
35. Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer 1997; 79: 1548-1551.
36. Steensma DP, Tefferi A. The myelodysplastic syndrome(s): A perspective and review highlighting current controversies. Leuk Res 2003; 27: 95-120.
37. List AF, Vardiman J, Issa JP, DeWitte TM. Myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program) 2004; 297-317.
38. Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002; 137: 156-163.
39. Sloand EM, Mainwaring L, Fuhrer M, Ramkissoon S, Risitano AM, Keyvanafar K et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005; 106: 841-851.
40. Hazenberg MD, Otto SA, Cohen Stuart JW, Verschuren MC, Borleffs JC. Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med 2000; 6: 1036-1042.
41. Goronzy JJ, Weyand CM. Thymic function and peripheral T-cell homeostasis in rheumatoid arthritis. Trends Immunol 2001; 22: 251-255.
42. Weyand CM, Goronzy JJ. T-cell responses in rheumatoid arthritis: systemic abnormalities-local disease. Curr Opin Rheumatol 1999; 11: 210-217.
43. Sloand EM, Kim S, Fuhrer M, Risitano AM, Nakamura R, Maciejewski JP et al. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood 2002; 100: 4427-4432.
44. Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A et al. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998; 103: 176-188.
45. Powers MP, Nishino H, Luo Y, Raza A, Vanguri A, Rice L et al. Polymorphisms in TGFbeta and TNFalpha are associated with the myelodysplastic syndrome phenotype. Arch Pathol Lab Med 2007; 131: 1789-1793.
46. Galili N, Cerny J, Raza A. Current treatment options: Impact of cytogenetics on the course of myelodysplasia. Curr Treat Options Oncol 2007; 8: 117-128.
47. Reza S, Dar S, Andric T, Qawi H, Mundle S, Shetty V et al. Biologic characteristics of 164 patients with myelodysplastic syndromes. Leuk Lymphoma 1999; 33: 281-287.
48. Reza S, Shetty V, Dar S, Qawi H, Raza A. Tumor necrosis factor-alpha levels decrease with anticytokine therapy in patients with myelodysplastic syndromes. J Interferon Cytokine Res 1998; 18 871-877.
49. Clarke SR, Rudensky AY. Survival and homeostatic proliferation of naive peripheral CD4+ T cells in the absence of self peptide: MHC complexes. J Immunol 2000; 165: 2458-2464.
50. Lim HW, Kim CH. Loss of IL-7 receptor alpha on CD4+ T cells defines terminally differentiated B cell-helping effector T cells in a B cell-rich lymphoid tissue. J Immunol 2007; 179: 7448-7456.
51. Chiu WK, Fann M, Weng NP. Generation and growth of CD28nullCD8+ memory T cells mediated by IL-15 and its induced cytokines. J Immunol 2006; 177: 7802-7810.
52. Stockinger B, Kassiotis G, Bourgeois C. Homeostasis and T cell regulation. Curr Opin Immunol 2004; 16: 775-779.
53. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005; 201: 723-735.
54. Neujahr DC, Chen C, Huang X, Markmann JF, Cobbold S, Waldman H et al Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J Immunol 2006; 176: 4632-4639.
55. Calzascia T, Pellegrini M, Lin A, Garza KM, Elford AR, Shahinian A et al. CD4T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity. Proc Natl Acad Sci USA 2008; 105: 2999-3004.
56. Dunham RM, Cervasi B, Brenchley JM, Albrecht H, Weintrob A, Sumpter B et al. CD127 and CD25 expression defines CD4+ T cell subsets that are differentially depleted during HIV infection. J Immunol 2008; 180: 5582-5592.
57. Vrabelova Z, Hrotekova Z, Hladikova Z, Bohmova K, Stechova K, Michalek J. CD 127- and FoxP3+ expression on CD25+CD4+ T regulatory cells upon specific diabetogeneic stimulation in high-risk relatives of type 1 diabetes mellitus patients. Scand J Immunol 2008; 67: 404-410.
58. Alves NL, van Leeuwen EM, Remmerswaal EB, Vrisekoop N, Tesselaar K, Roosnek E et al. A new subset of human naive CD8+ T cells defined by low expression of IL-7R alpha. J Immunol 2007; 179: 221-228.
59. Valencic E, Piscianz E, Tommasini A, Granzotto M. T cells stimulated in vitro have a suppressive function but do not contain only regulatory T cells. Clin Exp Immunol 2007; 150: 561-566.
60. Catalfamo M, Tai X, Karpova T, McNally J, Henkart PA. TcR-induced regulated secretion leads to surface expression of CTLA-4 in CD4(+)CD25(+) T cells. Immunology 2008; 125: 70-79.
61. Kordasti SY, Ingram W, Hayden J, Darling D, Barber L, Afzal B et al CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007; 110: 847-850.
62. King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004; 117: 265-277.